Impact of pharmacy channel on adherence to oral oncolytics

Table 1 Characteristics of patients according to pharmacy channel where index oral oncolytic prescription was filled^a

Characteristic^b	Specialty		Traditional Retail		P-value
Number of Patients	11,972		30,394
Row Percent	28.3%		71.7%
Mean (SD) Age	63.9 (12.5)		64.4 (12.9)		<0.001
Age Group, N (%):					<0.001
18–34 years	178	1.5%	493	1.6%
35–44 years	620	5.2%	1616	5.3%
45–54 years	1895	15.8%	4710	15.5%
55–64 years	3452	28.8%	8239	27.1%
65–74 years	3032	25.3%	7662	25.2%
75–84 years	2625	21.9%	6734	22.2%
85+ years	170	1.4%	940	3.1%
Male, N (%):	5416	45.2%	13,068	43.0%	<0.001
Region, N (%):					<0.001
Northeast	3531	29.5%	6439	21.2%
Midwest	2054	17.2%	6217	20.5%
South	4173	34.9%	10,960	36.1%
West	1813	15.1%	5107	16.8%
Unknown	401	3.3%	1671	5.5%
Index Study Year, N (%)					<0.001
2007	1118	9.3%	2670	8.8%
2008	2118	17.7%	5880	19.4%
2009	2860	23.9%	8176	26.9%
2010	3451	28.8%	8240	27.1%
2011	2425	20.3%	5428	17.9%
Index Oncolytic Received, N (%)					<0.001
Erlotinib	4774	39.9%	10,297	33.9%
Capecitabine	4906	41.0%	15,156	49.9%
Imatinib	2292	19.1%	4941	16.3%
Copay^c Amount Categorized					<0.001
$0–49	7112	59.4%	16,921	55.7%
$50–100	1572	13.1%	4127	13.6%
$101–150	761	6.4%	1877	6.2%
$151–200	350	2.9%	920	3.0%
$201–250	257	2.2%	656	2.2%
$251–350	199	1.7%	651	2.1%
$351–500	268	2.2%	900	3.0%
$501–1000	694	5.8%	2137	7.0%
> $1000	759	6.3%	2205	7.3%
Mean (SD) Copay^c Amount (per 30 days)	220.7 (548.2)		256.1 (595.31)		<0.001
P25	16.4		15.0
Median	36.0		40.0
P75	111.4		142.86
Mean (SD) Days Supplied Per Prescription	33.7 (20.7)		25.0 (12.5)		<0.001
Median	30.0		26.4

Note: Study index date refers to the first date that a patient attempted to fill the index oral oncolytic prescription.
Abbreviations: SD, standard deviation; N, number of patients; P25, 25th percentile; P75, 75th percentile
^aPharmacy channel defined based on the channel where patient filled their initial (index) oral oncolytic
^bGroup comparisons were made using 2-sided Pearson chi-square for categorical measures, t-test statistic for mean age and Wilcoxon test for mean copay, P-values are presented for comparisons using traditional retail as reference group
^cMean copay amount (per 30 day supply) calculated using patients’ prescription drug claims for index oral oncolytic from study index until end of follow-up and inflated to 2011 US dollars

ISSN: 1472-6963